Xerostomia Clinical Trial
Official title:
A Comparative Study of a Self-adhering Material in Dental Hypersensitivity in Xerostomic Patients Due to Radiotherapy
Aim: To compare the desensitizing capacity of Vertise Flow™ (VF), a new self adhering
material, in the treatment of dentine hypersensitivity (DH) in patients who are xerostomic
due to radiotherapy for head and neck cancer.
Methods: A total of 17 patients were selected for the study. The study was conducted as a
split-mouth randomized clinical trial comparing: 1) VF 2) Universal Dentin Sealant (UDS), 3)
Clearfil Protect Bond (CPB) and 4) Flor-Opal® Varnish (FOV). Basal and stimulated salivary
flow was recorded for each patient according to the method described by Sreebny. The pain
experience was generated by a cold stimulus directly to a sensitive tooth surface and
assessed using the Visual Analogue Scale (VAS). The response was recorded before the
application of the materials (PRE-1), immediately after (POST-1), at 1-week (POST-2),
4-weeks (POST-3) and 12-week controls (POST-4).
Participants The study was designed as a split-mouth randomized clinical trial. The protocol
and informed consent forms were approved by the ethics committee at the University of
Sassari (n° 1000/CE).
To participate in the study, all the subjects were carefully informed about the study's
purpose, risks and benefits.
The study inclusion criteria were the following:
- Generally good health despite the seriousness of their illness;
- A clinical reduction of salivary flow;
- The presence of two or three teeth which were hypersensitive to stimulation with a
blast of air.
In addition, patients were considered suitable for the study if they had sensitive teeth
showing abrasion, erosion or recession with the exposure of the cervical dentine.
The study exclusion criteria were:
- teeth with subjective or objective evidence of carious lesions, pulpitis, restorations,
premature contact, cracked enamel, active periapical infection or that had received
periodontal surgery or root-planning up to 6 months prior to the investigation;
- patients who had received professional desensitizing therapy during the previous 3
months;
- patients who had used desensitizing toothpaste in the last 6 weeks. Patients were also
excluded if they were under significant medication that could have interfered with pain
perception (e.g., antidepressants, anti-inflammatory drugs, sedatives, and muscle
relaxants).
Clinical Procedure
Saliva collection
All salivary assessments were performed in the absence of acute sialadenitis. All
assessments were performed by the same observer. The flow rate was determined in every
person according to the method described by Sreebny. Saliva was collected in a standardised
manner. Patients were instructed not to eat, drink, or smoke for 90 minutes before the
sialometric assessment. All assessments were performed at a fixed time of the day, between
10 am and 1 pm, in order to minimise fluctuations related to a circadian rhythm of salivary
secretion and composition. The whole saliva sample was collected in pre-weighed plastic
tubes using electronic scales.
Unstimulated salivary secretions were collected for 5 min with the patient seated in an
upright position, with the head tilted forward . When possible the tongue, cheek and lip
movements were limited during the procedure. At the end of the collection period the patient
had to expectorate saliva into the test-tube. Stimulated whole saliva samples were collected
by asking patients to chew a small block of paraffin wax or chewing gum. All the saliva
secreted for 5 min was then collected in the test-tube. Measuring vessels were weighed after
each collection using an electronic scales, and salivary flow rate was expressed in ml/min,
which is nearly equivalent to g/min (31). A secretion rate < 0.1-0.2 ml/min for unstimulated
flow and < 0.5-0.7 ml/min for stimulated flow was considered as an objective sign of
hyposalivation.
Assessment of hypersensitivity and application of desensitizing agents.
A week before the experiment, patients received oral prophylaxis. Non-fluoride toothpaste
(Biorepair, Coswell), a soft toothbrush (Oral-B Sensitive Advantage, Procter & Gamble) and
oral hygiene instructions were also provided. The level of sensitivity experienced by each
patient was considered as independent of the position of the hypersensitive tooth in the
oral cavity. The pain experience was assessed by a Visual Analogue Scale (VAS) using the
methodology described in our previous study. The pain experience was measured using a VAS
graded from 1 to 10. The pain stimulus was given by one examiner with the same equipment
yielding similar air pressure each time, while another one performed the treatments. The
same operator carried out the sensitivity test evaluating the subject's response before the
application of the materials (PRE-1), immediately after (POST-1), after 1 week (POST-2), 4
weeks (POST-3), and 12 weeks (POST-4) .
The following dental materials were used following the manufacturers' instructions: Verities
Flow™ (VF) (Kerr Corporation, Orange, CA, USA), a self-adhering composite; Universal Dentin
Sealant (UDS) (Ultradent Products Inc., South Jordan, UT, USA), a biocompatible,
non-polymerizable, high molecular weight resin sealant in alcohol solvent; Clearfil Protect
Bond (CPB), (Kuraray Noritake Dental, Osaka, Japan) a methacrylate-based resin, self-etching
adhesive system, and Flor-Opal® Varnish (FOV), (Ultradent Products Inc., South Jordan, UT,
USA), a fluoride-based varnish.
In view of the treatment with the desensitizing agents, teeth were randomly assigned into
four groups (N = per group).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05342272 -
Comparison of Gum® HydralTM Moisturizing Gel and Biotene® Oral Gel in Dry Mouth Sensation Reduction
|
Phase 3 | |
Completed |
NCT03302676 -
The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors
|
N/A | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Completed |
NCT01272570 -
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
|
N/A | |
Completed |
NCT00656513 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00911768 -
Effect of Korean Red Ginseng (KRG) on Dry Mouth
|
Phase 4 | |
Completed |
NCT00332618 -
Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia
|
Phase 2 | |
Completed |
NCT03494985 -
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
|
N/A | |
Completed |
NCT05058430 -
SaliPen Human Factors Study for OTC Labeling
|
N/A | |
Recruiting |
NCT02705937 -
Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.
|
N/A | |
Completed |
NCT05247008 -
Effectiveness of Thyme Honey in Management of Xerostomia in ESRD
|
N/A | |
Recruiting |
NCT03632096 -
Photobiomodulation in Salivary Production of Patients With Xerostomy
|
Phase 2 | |
Not yet recruiting |
NCT04323384 -
The Effect of Biotene® on the Symptoms of Xerostomia and Mastication and Swallowing
|
N/A | |
Not yet recruiting |
NCT03530735 -
Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
|
N/A | |
Active, not recruiting |
NCT03176368 -
Coconut Oil: Managing Radiation-Induced Xerostomia
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Completed |
NCT02682199 -
Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
|
||
Withdrawn |
NCT01960101 -
Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication
|
N/A | |
Completed |
NCT02317172 -
Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases
|
N/A |